A. Rosenwald, G. Wright, and K. Leroy, Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma, The Journal of Experimental Medicine, vol.81, issue.6, pp.851-862, 2003.
DOI : 10.1084/jem.20022089

K. Savage, S. Monti, and J. Kutok, The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma, Blood, vol.102, issue.12, pp.3871-3879, 2003.
DOI : 10.1182/blood-2003-06-1841

K. Dunleavy and W. Wilson, Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?, Blood, vol.125, issue.1, pp.33-39, 2015.
DOI : 10.1182/blood-2014-05-575092

C. Steidl and R. Gascoyne, The molecular pathogenesis of primary mediastinal large B-cell lymphoma, Blood, vol.118, issue.10, pp.2659-2669, 2011.
DOI : 10.1182/blood-2011-05-326538

J. Gunawardana, F. Chan, and A. Telenius, Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma, Nature Genetics, vol.362, issue.4, pp.329-335, 2014.
DOI : 10.1038/ng.2900

N. Gebauer, T. Hardel, and J. Gebauer, Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma, Anticancer research, vol.34, pp.5503-5507, 2014.

S. Mareschal, S. Dubois, and P. Viailly, Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes, Chromosomes and Cancer, vol.110, issue.3, 2015.
DOI : 10.1002/gcc.22328

URL : https://hal.archives-ouvertes.fr/hal-01237083

S. Dubois, P. Viailly, and S. Mareschal, Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. Clinical cancer research : an official journal of the, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01442496

S. Jeromin, S. Weissmann, and C. Haferlach, SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.98, issue.1, pp.108-117, 2014.
DOI : 10.1038/leu.2013.263

D. Lin, J. Hao, and Y. Nagata, Genomic and molecular characterization of esophageal squamous cell carcinoma Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL, Nature genetics Blood, vol.46124, issue.11, pp.467-4733023, 2014.

J. Etchin, T. Sanda, and M. Mansour, KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia, British journal of haematology Blood, vol.161120, issue.13, pp.117-1274621, 2012.

F. Peyrade, F. Jardin, and C. Thieblemont, Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial, The Lancet Oncology, vol.12, issue.5, pp.460-468, 2011.
DOI : 10.1016/S1470-2045(11)70069-9

C. Recher, B. Coiffier, and C. Haioun, Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial, The Lancet, vol.378, issue.9806, pp.1858-1867, 2011.
DOI : 10.1016/S0140-6736(11)61040-4

R. Delarue, H. Tilly, and N. Mounier, Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.6, pp.525-533, 2013.
DOI : 10.1016/S1470-2045(13)70122-0

O. Fitoussi, K. Belhadj, and N. Mounier, Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA, Haematologica, vol.96, issue.8, pp.1136-1143, 2011.
DOI : 10.3324/haematol.2010.038109

N. Ketterer, B. Coiffier, and C. Thieblemont, Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) Annals of oncology : official journal of the European Society for Medical Oncology Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma, ESMO The American journal of surgical pathology, vol.2429, pp.1032-10371411, 2005.

P. Moller, S. Bruderlein, and J. Strater, MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma, International Journal of Cancer, vol.75, issue.3, pp.348-353, 2001.
DOI : 10.1002/ijc.1211

E. Nacheva, M. Dyer, and C. Metivier, B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression, Blood, vol.84, pp.3422-3428, 1994.

C. Sambade, M. Berglund, and S. Lagercrantz, U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma, International Journal of Cancer, vol.30, issue.Suppl 1, pp.555-5631, 2006.
DOI : 10.1002/ijc.21417

S. Mareschal, S. Dubois, and T. Lecroq, Rgb: a scriptable genome browser for R, Bioinformatics, vol.30, issue.15, pp.2204-2205, 2014.
DOI : 10.1093/bioinformatics/btu185

Q. Li, N. Birkbak, and B. Gyorffy, Jetset: selecting the optimal microarray probe set to represent a gene limma powers differential expression analyses for RNAsequencing and microarray studies Nucleic acids research 2015 A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, BMC bioinformatics Cancer cell Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.12417, issue.28, pp.474-26463, 1999.

X. Dong, A. Biswas, and K. Suel, Structural basis for leucine-rich nuclear export signal recognition by CRM1 Evaluation of structural and evolutionary contributions to deleterious mutation prediction A general framework for estimating the relative pathogenicity of human genetic variants, Nature Journal of molecular biology Nature genetics, vol.45832246, issue.30, pp.1136-1141891, 2002.

S. Joos, M. Otano-joos, and S. Ziegler, Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene, Blood, vol.87, pp.1571-1578, 1996.

M. Weniger, S. Gesk, and S. Ehrlich, Gains ofREL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein, Genes, Chromosomes and Cancer, vol.82, issue.4, pp.406-415, 2007.
DOI : 10.1002/gcc.20420

G. Lenz, G. Wright, and N. Emre, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proceedings of the National Academy of Sciences, vol.105, issue.36, pp.13520-13525, 2008.
DOI : 10.1073/pnas.0804295105

J. Reichel, A. Chadburn, and P. Rubinstein, Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells, Blood, vol.125, issue.7, pp.1061-1072, 2015.
DOI : 10.1182/blood-2014-11-610436

R. Aguiar, K. Takeyama, and C. He, B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity, Journal of Biological Chemistry, vol.280, issue.40, pp.33756-33765, 2005.
DOI : 10.1074/jbc.M505408200

X. Han, J. Wang, and Y. Shen, CRM1 as a new therapeutic target for non-Hodgkin lymphoma, Leukemia Research, vol.39, issue.1, pp.38-46, 2015.
DOI : 10.1016/j.leukres.2014.10.003

Y. Tai, Y. Landesman, and C. Acharya, CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications, Leukemia, vol.69, issue.1, pp.155-165, 2014.
DOI : 10.1038/leu.2013.115

M. Weniger, I. Melzner, and C. Menz, Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation, Oncogene, vol.28, issue.18, pp.2679-2684, 2006.
DOI : 10.1038/sj.onc.1209151

O. Ritz, C. Guiter, and F. Castellano, Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma, Blood, vol.114, issue.6, pp.1236-1242, 2009.
DOI : 10.1182/blood-2009-03-209759

URL : https://hal.archives-ouvertes.fr/inserm-00411059

K. Dunleavy, C. Grant, and F. Eberle, Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Current hematologic malignancy reports 2012 Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?, Blood, vol.7125, issue.42, pp.241-24733, 2015.

F. Feuerhake, J. Kutok, and S. Monti, NF??B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes, Blood, vol.106, issue.4, pp.1392-1399, 2005.
DOI : 10.1182/blood-2004-12-4901

J. Yuan, G. Wright, and A. Rosenwald, Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling, The American Journal of Surgical Pathology, vol.39, issue.10, pp.1322-1330, 2015.
DOI : 10.1097/PAS.0000000000000473

I. Melzner, A. Bucur, and S. Bruderlein, Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1, Blood The Journal of cell biology, vol.105165, issue.46, pp.2535-2542823, 2004.

C. Steidl, S. Shah, and B. Woolcock, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, vol.100, issue.7338, pp.377-381, 2011.
DOI : 10.1038/nature09754

L. Xie, O. Ritz, and F. Leithauser, FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma, Oncotarget, vol.5, issue.14, pp.5392-5402, 2014.
DOI : 10.18632/oncotarget.2107

L. Mao, Y. Y. Raval, A. Weissman, J. Howcroft, and T. , Targeting the nuclear transport machinery by rational drug design The GTP-binding domain of class II transactivator regulates its nuclear export, Current pharmaceutical design J Immunol, vol.19170, issue.50, pp.2318-2325922, 2003.

I. Muqbil, M. Kauffman, and S. Shacham, Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling, Current Pharmaceutical Design, vol.20, issue.1, pp.56-65, 2014.
DOI : 10.2174/13816128113199990611

URL : http://doi.org/10.2174/13816128113199990611

I. Swameye, T. Muller, and J. Timmer, Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling Identifying drug-target selectivity of smallmolecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing Nucleo-cytoplasmic transport as a therapeutic target of cancer Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma, Proceedings of the National Academy of Sciences of the United States of America Chemistry & biology Journal of hematology & oncology Cancer Sci, vol.100227105, issue.55, pp.1028-1033, 2003.